ArticleJournal of addiction medicine2026
Association of Emergency Department Buprenorphine Initiation With Subsequent Pharmacotherapy and Outcomes Among Patients With Opioid Use Disorder.
Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo examine trends in emergency department (ED) buprenorphine initiation and evaluate its association with outcomes in the 180 days following discharge.
methodsThis observational cohort study used 2018-2022 New Jersey Medicaid claims data from patients presenting to EDs for opioid-related causes, excluding visits that resulted in inpatient admission. We used prescription and encounter data to identify patients with opioid use disorder (OUD) or opioid overdose who initiated buprenorphine in the ED and propensity score matching to compare outcomes of initiators and noninitiators. Outcomes measured during 180-day follow-up were the proportion of days covered (PDC) with medication for OUD (MOUD) and the number of drug overdoses, opioid overdoses, and all-cause ED/inpatient visits within 180 days.
resultsBuprenorphine was initiated in 978 of 24,732 (4.0%) opioid-related ED visits, with this proportion increasing from 0.8% in 2018 to 7.1% in 2022. Buprenorphine initiation was associated with greater MOUD PDC (β=0.10, 95% CI: 0.08-0.13) and fewer all-cause ED/inpatient visits (IRR=0.87, 95% CI: 0.77-0.98) during follow-up. We did not find a statistically significant association between ED buprenorphine initiation and postdischarge overdose; however, greater PDC in the 180-day follow-up period was associated with fewer drug overdoses (IRR=0.80, 95% CI: 0.68-0.94), opioid overdoses (IRR=0.78, 95% CI: 0.67-0.91), and all-cause ED/inpatient visits (IRR=0.89, 95% CI: 0.82-0.96).
conclusionsEDs play a central role in initiating patients on MOUD, but longer-term outcomes likely depend on multiple factors that may go beyond the scope of ED practice. Further efforts are needed to support MOUD retention and reduce the risk of adverse outcomes following opioid-related ED visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.